Pentixapharm Holding AG (VIE:PTPN)

Austria · Delayed Price · Currency is EUR

1.885

+0.015 (0.80%)

At close: Sep 9, 2026

Market Cap	45.85M +10.1%
Revenue (ttm)	242.00K -86.5%
Net Income	-15.03M
EPS	-0.61
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	1.875
Previous Close	1.870
Day's Range	1.875 - 1.885
52-Week Range	1.330 - 3.550
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About Pentixapharm Holding AG

Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 binding, peptide-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based on Yttrium-90 and Lutetium-177, for the treatment of leukemia, which is... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances

Founded 2019

Employees 38

Stock Exchange Vienna Stock Exchange

Ticker Symbol PTPN

Financial Performance

In 2025, Pentixapharm Holding AG's revenue was 526,000, a decrease of -63.28% compared to the previous year's 1.43 million. Losses were -16.51 million, 26.4% more than in 2024.

Financial Statements